<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39442113</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1726-4642</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Revista peruana de medicina experimental y salud publica</Title><ISOAbbreviation>Rev Peru Med Exp Salud Publica</ISOAbbreviation></Journal><ArticleTitle>Characteristics of COVID-19-associated multisystemic inflammatory syndrome in children treated in a Peruvian hospital, 2020-2022.</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>308</EndPage><MedlinePgn>301-308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.17843/rpmesp.2024.413.13736</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Motivation for the study. There are few studies describing the variation of COVID-19-associated multisystem inflammatory syndrome (MIS-C) in Peru across pandemic waves.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Main findings. Cases of MIS-C decreased during the first three years of the pandemic, with higher frequency in the second wave with clinical features similar to Kawasaki disease.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Implications. MIS-C is a post-infectious complication of SARS-CoV-2. Its diagnostic suspicion is important weeks after peak infections, especially in children who have not yet received COVID-19 vaccines.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to describe the characteristics of multisystemic inflammatory syndrome associated with COVID-19 (MIS-C) in the first three years of the pandemic in children in a pediatric hospital in Peru. We conducted an observational, descriptive study with data from 73 patients and described the clinical and laboratory characteristics, treatment and complications according to the wave of the pandemic and whether they had shock. The median age was 6 years, gastrointestinal and mucocutaneous manifestations were frequent in the three waves. Kawasaki disease-like phenotype was present in 34 (46.6%) patients and 21 (28.8%) patients developed shock. The most commonly used treatment was immunoglobulin (95.9%), followed by acetylsalicylic acid (94.5%) and corticosteroid (86.3%). Five (7%) patients had coronary aneurysm and 17 (23.3%) were admitted to the intensive care unit (ICU). Patients with shock had greater laboratorial alteration and need for mechanical ventilation. In conclusion, MIS-C has decreased in the first three years of the pandemic, possibly due to COVID-19 vaccination in children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Atamari-Anahui</LastName><ForeName>Noé</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8283-6669</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huby-Muñoz</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7465-1533</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad San Martín de Porres, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peña-Coello</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4319-5234</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad San Martín de Porres, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillen-Buleje</LastName><ForeName>Deli</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3049-9901</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad San Martín de Porres, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Martinez</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1346-9994</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuñez-Paucar</LastName><ForeName>Héctor</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3995-2079</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamudio-Aquise</LastName><ForeName>Mariela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3451-0629</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernal-Mancilla</LastName><ForeName>Raúl</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5676-7284</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Nacional Mayor de San Marcos, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Coll-Vela</LastName><ForeName>Liz</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8709-397X</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Nacional Mayor de San Marcos, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orellana-Siuce</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0075-7495</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Candela-Herrera</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6529-8459</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Salud del Niño-Breña, Lima, Perú.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Características del síndrome inflamatorio multisistémico asociado a COVID-19 en niños atendidos en un hospital peruano, 2020-2022.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Peru</Country><MedlineTA>Rev Peru Med Exp Salud Publica</MedlineTA><NlmUniqueID>101227566</NlmUniqueID><ISSNLinking>1726-4634</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010568" MajorTopicYN="N" Type="Geographic">Peru</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="Y">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006776" MajorTopicYN="N">Hospitals, Pediatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009080" MajorTopicYN="N">Mucocutaneous Lymph Node Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">El propósito del estudio fue describir las características del síndrome inflamatorio multisistémico asociado a COVID-19 (SIM-C) en los primeros tres años de pandemia en niños de un hospital pediátrico del Perú. Se realizó un estudio observacional, descriptivo con datos de 73 pacientes y se describieron las características clínicas, laboratoriales, tratamiento y complicaciones según la ola de la pandemia y si tuvieron shock. La mediana de edad fue 6 años, las manifestaciones gastrointestinales y mucocutáneas fueron frecuentes en las tres olas. El fenotipo similar a enfermedad de Kawasaki se presentó en 34 (46,6%) pacientes y 21 (28,8%) pacientes desarrollaron shock. El tratamiento más usado fue la inmunoglobulina (95,9%), ácido acetil salicílico (94,5%) y corticoide (86,3%). Cinco (7%) pacientes tuvieron aneurisma coronario y 17 (23,3%) ingresaron a la unidad de cuidados intensivos (UCI). Los pacientes con shock tuvieron mayor alteración laboratorial y necesidad de ventilación mecánica. En conclusión, el SIM-C ha disminuido en los primeros tres años de pandemia posiblemente por la vacunación de COVID-19 en niños.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Motivación para realizar el estudio. Existen limitados estudios que describan la variación del síndrome inflamatorio multisistémico asociado a COVID-19 (SIM-C) en Perú a través de las olas de la pandemia.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Principales hallazgos. En los primeros tres años de pandemia los casos de SIM-C disminuyeron, con mayor la frecuencia en la segunda ola con características clínicas similares a la enfermedad de Kawasaki.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Implicancias. El SIM-C es una complicación posinfecciosa del SARS-CoV-2. Es importante su sospecha diagnóstica semanas posteriores a los picos de contagios, especialmente en los niños que aún no han recibido vacunas contra la COVID-19.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El propósito del estudio fue describir las características del síndrome inflamatorio multisistémico asociado a COVID-19 (SIM-C) en los primeros tres años de pandemia en niños de un hospital pediátrico del Perú. Se realizó un estudio observacional, descriptivo con datos de 73 pacientes y se describieron las características clínicas, laboratoriales, tratamiento y complicaciones según la ola de la pandemia y si tuvieron shock. La mediana de edad fue 6 años, las manifestaciones gastrointestinales y mucocutáneas fueron frecuentes en las tres olas. El fenotipo similar a enfermedad de Kawasaki se presentó en 34 (46,6%) pacientes y 21 (28,8%) pacientes desarrollaron shock. El tratamiento más usado fue la inmunoglobulina (95,9%), ácido acetil salicílico (94,5%) y corticoide (86,3%). Cinco (7%) pacientes tuvieron aneurisma coronario y 17 (23,3%) ingresaron a la unidad de cuidados intensivos (UCI). Los pacientes con shock tuvieron mayor alteración laboratorial y necesidad de ventilación mecánica. En conclusión, el SIM-C ha disminuido en los primeros tres años de pandemia posiblemente por la vacunación de COVID-19 en niños.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest.:</b> The authors deny any conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>22</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>22</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>16</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39442113</ArticleId><ArticleId IdType="pmc">PMC11495924</ArticleId><ArticleId IdType="doi">10.17843/rpmesp.2024.413.13736</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276–e288. doi: 10.1016/S1473-3099(20)30651-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30651-4</ArticleId><ArticleId IdType="pmc">PMC7431129</ArticleId><ArticleId IdType="pubmed">32818434</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Netw Open. 2021;4(6):e2116420. doi: 10.1001/jamanetworkopen.2021.16420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.16420</ArticleId><ArticleId IdType="pmc">PMC8193431</ArticleId><ArticleId IdType="pubmed">34110391</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruvinsky S, Voto C, Roel M, Fustiñana A, Veliz N, Brizuela M. Multisystem Inflammatory Syndrome Temporally Related to COVID-19 in Children From Latin America and the Caribbean Region A Systematic Review With a Meta-Analysis of Data From Regional Surveillance Systems. Front Pediatr. 2022;10:881765–881765. doi: 10.3389/fped.2022.881765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.881765</ArticleId><ArticleId IdType="pmc">PMC9082071</ArticleId><ArticleId IdType="pubmed">35547540</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Perramon A, Català M, Torres JP, Camacho-Moreno G, Rojas-Solano M. Multisystemic Inflammatory Syndrome in Children in Western Countries Decreasing Incidence as the Pandemic Progresses?: An Observational Multicenter International Cross-sectional Study. Pediatr Infect Dis J. 2022;41(12):989–993. doi: 10.1097/INF.0000000000003713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003713</ArticleId><ArticleId IdType="pmc">PMC9645445</ArticleId><ArticleId IdType="pubmed">36102705</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm M, Espenhain L, Glenthøj J, Schmidt LS, Nordly SB, Hartling UB. Risk and Phenotype of Multisystem Inflammatory Syndrome in Vaccinated and Unvaccinated Danish Children Before and During the Omicron Wave. JAMA Pediatr. 2022;176(8):821–823. doi: 10.1001/jamapediatrics.2022.2206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.2206</ArticleId><ArticleId IdType="pmc">PMC9178498</ArticleId><ArticleId IdType="pubmed">35675054</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020;324(3):259–269. doi: 10.1001/jama.2020.10369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10369</ArticleId><ArticleId IdType="pmc">PMC7281356</ArticleId><ArticleId IdType="pubmed">32511692</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-Gómez HR, Morfín-Otero R, González-Díaz E, Esparza-Ahumada S, León-Garnica G, Rodríguez-Noriega E. The Multifaceted Manifestations of Multisystem Inflammatory Syndrome during the SARS-CoV-2 Pandemic. Pathogens. 2022;11(5):556–556. doi: 10.3390/pathogens11050556.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11050556</ArticleId><ArticleId IdType="pmc">PMC9143280</ArticleId><ArticleId IdType="pubmed">35631077</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfred-Cato S, Abrams JY, Balachandran N, Jaggi P, Jones K, Rostad CA. Distinguishing Multisystem Inflammatory Syndrome in Children From COVID-19, Kawasaki Disease and Toxic Shock Syndrome. Pediatr Infect Dis J. 2022;41(4):315–323. doi: 10.1097/INF.0000000000003449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003449</ArticleId><ArticleId IdType="pmc">PMC8919949</ArticleId><ArticleId IdType="pubmed">35093995</ArticleId></ArticleIdList></Reference><Reference><Citation>Acevedo L, Piñeres-Olave BE, Niño-Serna LF, Vega LM, Gomez IJA, Chacón S. Mortality and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with covid-19 in critically ill patients an observational multicenter study (MISCO study) BMC Pediatr. 2021;21(1):516–516. doi: 10.1186/s12887-021-02974-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-021-02974-9</ArticleId><ArticleId IdType="pmc">PMC8600488</ArticleId><ArticleId IdType="pubmed">34794410</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Sarmiento J, Acevedo L, Niño-Serna LF, Boza R, García-Silva J, Yock-Corrales A, et al. Risk Factors Associated with Intensive Care Admission in Children with Severe Acute Respiratory Syndrome Coronavirus 2-Related Multisystem Inflammatory Syndrome (MIS-C) in Latin America: A Multicenter Observational Study of the REKAMLATINA Network. J Intensive Care Med. 2024 doi: 10.1177/08850666241233189. 08850666241233189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08850666241233189</ArticleId><ArticleId IdType="pubmed">38414438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain PN, Acosta S, Annapragada A, Checchia PA, Moreira A, Muscal E. Comparison of Laboratory and Hemodynamic Time Series Data Across Original, Alpha, and Delta Variants in Patients With Multisystem Inflammatory Syndrome in Children. Pediatr Crit Care Med. 2022;23(8):e372. doi: 10.1097/PCC.0000000000002976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000002976</ArticleId><ArticleId IdType="pmc">PMC9345524</ArticleId><ArticleId IdType="pubmed">35507775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kechiche R, Borocco C, Bajolle F, Belot A, Poignant S, Lachaume N. Multisystem inflammatory syndrome in children during the COVID-19 waves data from the Juvenile Inflammatory Rheumatism cohort. Front Pediatr. 2023;24(11):1126985–1126985. doi: 10.3389/fped.2023.1126985.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2023.1126985</ArticleId><ArticleId IdType="pmc">PMC10246474</ArticleId><ArticleId IdType="pubmed">37292378</ArticleId></ArticleIdList></Reference><Reference><Citation>Angurana SK, Kumar V, Nallasamy K, Kumar MR, Naganur S, Kumar M. Clinico-Laboratory Profile, Intensive Care Needs and Short-Term Outcome of Multisystem Inflammatory Syndrome in Children (MIS-C) Experience during First and Second Waves from North India. J Trop Pediatr. 2022;68(5):fmac068–fmac068. doi: 10.1093/tropej/fmac068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/tropej/fmac068</ArticleId><ArticleId IdType="pubmed">36048462</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile A, Juárez MDV, Romero Bollon L, Aprea V, Matteucci E, Falaschi A. Comparison of Epidemiologic and Clinical COVID-19 Profiles in Children in Argentina, During Circulation of Original and Variant (Alpha, Gamma and Lambda) Strains. Pediatr Infect Dis J. 2023;42(2):136–136. doi: 10.1097/INF.0000000000003776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003776</ArticleId><ArticleId IdType="pmc">PMC9838605</ArticleId><ArticleId IdType="pubmed">36638400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ensinck G, Gregorio G, Flores RM, Crowe CI, Clerico Mosina P, Curi C. Consensus on treatment of multisystemic inflammatory syndrome associated with COVID-19. Arch Argent Pediatr. 2021;119(4):S198–S211. doi: 10.5546/aap.2021.S198.</Citation><ArticleIdList><ArticleId IdType="doi">10.5546/aap.2021.S198</ArticleId><ArticleId IdType="pubmed">34309328</ArticleId></ArticleIdList></Reference><Reference><Citation>Atamari-Anahui N, Ccorahua-Rios MS, Rodriguez-Camino MC, Santander-Cahuantico AC, Pacheco-Mendoza J. Bibliometric Analysis of Scientific Production in Scopus by the Instituto Nacional de Salud Del Niño-Breña, Peru, 2010-2019. Journal of Hospital Librarianship. 2022;22(2):108–120. doi: 10.1080/15323269.2022.2054601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15323269.2022.2054601</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo G, Cofré F, Poli C, Delpiano L, Conca N, Verdugo P. Recomendaciones para la sospecha diagnóstica y manejo del Síndrome Inflamatorio Multisistémico (SIM-COVID-19) en contexto pandemia SARS-CoV-2 Abril 2021. Rev Chil Infectol. 2021;38(3):370–380. doi: 10.4067/S0716-10182021000300370.</Citation><ArticleIdList><ArticleId IdType="doi">10.4067/S0716-10182021000300370</ArticleId><ArticleId IdType="pubmed">34479294</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarado-Gamarra G, Aguila del O, Dominguez-Rojas J, Chonlon-Murillo K, Atamari-Anahui N, Borcic A. Fenotipos clínicos del síndrome inflamatorio multisistémico pediátrico asociado a COVID-19 (SIM-C) Andes Pediatr. 2022;93(6):841–850. doi: 10.32641/andespediatr.v93i6.4084.</Citation><ArticleIdList><ArticleId IdType="doi">10.32641/andespediatr.v93i6.4084</ArticleId><ArticleId IdType="pubmed">37906801</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo-Castillo R. Dos años de pandemia, una batalla que aún no termina. Acta Médica Peru. 2022;39(1):3–6. doi: 10.35663/amp.2022.391.2374.</Citation><ArticleIdList><ArticleId IdType="doi">10.35663/amp.2022.391.2374</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll-Vela LED, Zamudio-Aquise MK, Nuñez-Paucar H, Bernal-Mancilla RR, Schult-Montoya SC, Ccorahua-De La Paz M, et al. Síndrome inflamatorio multisistémico asociado a COVID-19 en niños serie de casos en un hospital pediátrico de Perú. Rev Peru Med Exp Salud Publica. 2020;37(3):559–565. doi: 10.17843/rpmesp.2020.373.6126.</Citation><ArticleIdList><ArticleId IdType="doi">10.17843/rpmesp.2020.373.6126</ArticleId><ArticleId IdType="pubmed">33295562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):52–58. doi: 10.15585/mmwr.mm7102e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7102e1</ArticleId><ArticleId IdType="pmc">PMC8757620</ArticleId><ArticleId IdType="pubmed">35025852</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrindle Brian W, Rowley Anne H, Newburger Jane W, Burns Jane C, Bolger AF, Gewitz M. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135(17):e927–e999. doi: 10.1161/CIR.0000000000000484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000484</ArticleId><ArticleId IdType="pubmed">28356445</ArticleId></ArticleIdList></Reference><Reference><Citation>McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C. Treatment of Multisystem Inflammatory Syndrome in Children. N Engl J Med. 2021;385(1):11–22. doi: 10.1056/NEJMoa2102968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102968</ArticleId><ArticleId IdType="pmc">PMC8220965</ArticleId><ArticleId IdType="pubmed">34133854</ArticleId></ArticleIdList></Reference><Reference><Citation>Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. N Engl J Med. 2021;385(1):23–34. doi: 10.1056/NEJMoa2102605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102605</ArticleId><ArticleId IdType="pmc">PMC8220972</ArticleId><ArticleId IdType="pubmed">34133855</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>